MA52216B1 - Mirikizumab pour le traitement de la colite ulcéreuse - Google Patents

Mirikizumab pour le traitement de la colite ulcéreuse

Info

Publication number
MA52216B1
MA52216B1 MA52216A MA52216A MA52216B1 MA 52216 B1 MA52216 B1 MA 52216B1 MA 52216 A MA52216 A MA 52216A MA 52216 A MA52216 A MA 52216A MA 52216 B1 MA52216 B1 MA 52216B1
Authority
MA
Morocco
Prior art keywords
treatment
ulcerative colitis
mirikizumab
antibody
disease
Prior art date
Application number
MA52216A
Other languages
English (en)
Other versions
MA52216A (fr
Inventor
James Benedict CANAVAN
Stuart William FRIEDRICH
Kathryn Ann KRUEGER
Catherine MILCH
Jay Lawrence TUTTLE
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of MA52216A publication Critical patent/MA52216A/fr
Publication of MA52216B1 publication Critical patent/MA52216B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

  La présente invention concerne de manière générale le traitement de la colite ulcéreuse avec un anticorps anti-IL-23pl9, en particulier des schémas posologiques pour le traitement de la maladie.
MA52216A 2018-03-30 2019-03-28 Mirikizumab pour le traitement de la colite ulcéreuse MA52216B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650314P 2018-03-30 2018-03-30
PCT/US2019/024633 WO2019191464A1 (fr) 2018-03-30 2019-03-28 Méthodes de traitement de la colite ulcéreuse
EP19722256.5A EP3773715B1 (fr) 2018-03-30 2019-03-28 Mirikizumab pour le traitement de la colite ulcéreuse

Publications (2)

Publication Number Publication Date
MA52216A MA52216A (fr) 2021-02-17
MA52216B1 true MA52216B1 (fr) 2024-07-31

Family

ID=66429483

Family Applications (2)

Application Number Title Priority Date Filing Date
MA67901A MA67901B1 (fr) 2018-03-30 2019-03-28 Mirikizumab pour le traitement de la colite ulcéreuse
MA52216A MA52216B1 (fr) 2018-03-30 2019-03-28 Mirikizumab pour le traitement de la colite ulcéreuse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA67901A MA67901B1 (fr) 2018-03-30 2019-03-28 Mirikizumab pour le traitement de la colite ulcéreuse

Country Status (29)

Country Link
US (2) US12152072B2 (fr)
EP (2) EP3773715B1 (fr)
JP (4) JP7119114B2 (fr)
KR (1) KR102552693B1 (fr)
CN (1) CN111936165A (fr)
AU (2) AU2019243283C1 (fr)
BR (1) BR112020018099A2 (fr)
CA (1) CA3095297A1 (fr)
DK (2) DK3773715T3 (fr)
EA (1) EA202091989A1 (fr)
ES (2) ES2983809T3 (fr)
FI (2) FI3773715T3 (fr)
HR (2) HRP20240904T1 (fr)
HU (1) HUE067445T2 (fr)
IL (2) IL312807B2 (fr)
LT (2) LT4327866T (fr)
MA (2) MA67901B1 (fr)
MD (2) MD4327866T2 (fr)
MX (1) MX2020010269A (fr)
MY (1) MY202368A (fr)
PL (2) PL3773715T3 (fr)
PT (2) PT4327866T (fr)
RS (2) RS67806B1 (fr)
SG (1) SG11202009526RA (fr)
SI (2) SI4327866T1 (fr)
TW (2) TWI744617B (fr)
UA (1) UA128578C2 (fr)
WO (1) WO2019191464A1 (fr)
ZA (1) ZA202005388B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
WO2021161270A2 (fr) * 2020-02-14 2021-08-19 Janssen Biotech, Inc. Méthode sûre et efficace de traitement de la rectocolite hémorragique avec un anticorps anti-il-12/il23
MX2022014430A (es) 2020-05-21 2023-02-22 Janssen Biotech Inc Método para tratar la enfermedad inflamatoria del intestino con una terapia de combinación de anticuerpos para il-23 y tnf alfa.
JP7423815B2 (ja) * 2020-10-20 2024-01-29 セトラスホールディングス株式会社 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム
TW202241506A (zh) * 2021-01-06 2022-11-01 美商艾伯維有限公司 治療克羅恩氏病及潰瘍性結腸炎之方法
WO2022243937A1 (fr) * 2021-05-20 2022-11-24 Janssen Biotech, Inc. Méthode de traitement d'une maladie intestinale inflammatoire au moyen d'une polythérapie d'anticorps dirigés contre il-23 et tnf alpha
CA3219846A1 (fr) * 2021-05-28 2022-12-01 Venkatesh Krishnan Regulation d'anticorps anti-il-23p19 de genes impliques dans la rectocolite hemorragique
US20230159633A1 (en) * 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
JP2025539830A (ja) * 2022-11-22 2025-12-09 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で潰瘍性大腸炎を治療する方法
CN121079321A (zh) 2023-03-10 2025-12-05 伊莱利利公司 治疗溃疡性结肠炎的方法
WO2024255867A1 (fr) * 2023-06-16 2024-12-19 信达生物制药(苏州)有限公司 Utilisation d'un anticorps de sous-unité anti-interleukine 23p19 recombinant dans le traitement d'une maladie intestinale inflammatoire
WO2025170982A2 (fr) 2024-02-06 2025-08-14 Paragon Therapeutics, Inc. Compositions d'anticorps anti-il-23 et méthodes d'utilisation
WO2026060205A1 (fr) 2024-09-13 2026-03-19 Eli Lilly And Company Anticorps anti-pan-elr+ cxc chimiokines et anticorps anti-il-23p19 pour le traitement de la rectocolite hémorragique

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2452694B1 (fr) * 2005-06-30 2018-11-14 Janssen Biotech, Inc. Anticorps anti-IL-23, compositions, procédés et utilisations
RS55963B1 (sr) 2005-12-29 2017-09-29 Janssen Biotech Inc Humana anti-il-23 antitela, kompozicije, metode i upotrebe
DK2426144T3 (en) 2007-02-23 2019-01-07 Merck Sharp & Dohme Manipulated Anti-IL-23P19 Antibodies
WO2010062663A1 (fr) * 2008-11-03 2010-06-03 Schering Corporation Biomarqueurs de maladie inflammatoire de l'intestin et procédés apparentés du traitement
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
SG190006A1 (en) * 2010-11-04 2013-06-28 Boehringer Ingelheim Int Anti-il-23 antibodies
TWI636063B (zh) 2013-03-08 2018-09-21 美國禮來大藥廠 結合ｉｌ－２３之抗體
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
ES3064335T3 (en) * 2018-03-05 2026-04-24 Janssen Biotech Inc Methods of treating crohn's disease with anti-il23 specific antibody

Also Published As

Publication number Publication date
HRP20260275T1 (hr) 2026-04-10
US20210032325A1 (en) 2021-02-04
IL312807A (en) 2024-07-01
US20250034243A1 (en) 2025-01-30
HUE067445T2 (hu) 2024-10-28
AU2019243283B2 (en) 2023-07-27
MY202368A (en) 2024-04-24
ES2983809T3 (es) 2024-10-24
JP2025020134A (ja) 2025-02-12
KR102552693B1 (ko) 2023-07-07
IL312807B2 (en) 2025-06-01
RS65661B1 (sr) 2024-07-31
TW202206104A (zh) 2022-02-16
MX2020010269A (es) 2020-11-06
EP4327866A2 (fr) 2024-02-28
PT3773715T (pt) 2024-05-27
AU2023248103A1 (en) 2023-11-09
KR20200128101A (ko) 2020-11-11
EP4327866B1 (fr) 2025-12-10
JP2021517156A (ja) 2021-07-15
JP7331219B2 (ja) 2023-08-22
CA3095297A1 (fr) 2019-10-03
DK3773715T3 (da) 2024-05-27
JP2022169562A (ja) 2022-11-09
LT4327866T (lt) 2026-03-10
TWI837532B (zh) 2024-04-01
ZA202005388B (en) 2025-05-28
WO2019191464A1 (fr) 2019-10-03
AU2019243283A1 (en) 2020-09-24
BR112020018099A2 (pt) 2020-12-22
PL4327866T3 (pl) 2026-04-20
PT4327866T (pt) 2026-02-17
RS67806B1 (sr) 2026-03-31
UA128578C2 (uk) 2024-08-21
IL312807B1 (en) 2025-02-01
MA52216A (fr) 2021-02-17
IL277514B2 (en) 2024-11-01
NZ767902A (en) 2024-05-31
SI3773715T1 (sl) 2024-06-28
AU2023248103B2 (en) 2026-02-05
MD3773715T2 (ro) 2024-10-31
SG11202009526RA (en) 2020-10-29
FI4327866T3 (fi) 2026-02-18
CN111936165A (zh) 2020-11-13
IL277514B1 (en) 2024-07-01
TW201946657A (zh) 2019-12-16
DK4327866T3 (da) 2026-02-23
MD4327866T2 (ro) 2026-04-30
IL277514A (en) 2020-11-30
MA67901B1 (fr) 2026-02-27
EP3773715B1 (fr) 2024-05-08
PL3773715T3 (pl) 2024-08-19
US12152072B2 (en) 2024-11-26
HRP20240904T1 (hr) 2024-10-11
TWI744617B (zh) 2021-11-01
JP7571225B2 (ja) 2024-10-22
SI4327866T1 (sl) 2026-04-30
JP2023166388A (ja) 2023-11-21
LT3773715T (lt) 2024-06-25
FI3773715T3 (fi) 2024-05-30
JP7119114B2 (ja) 2022-08-16
EA202091989A1 (ru) 2021-01-13
AU2019243283C1 (en) 2024-05-02
ES3063700T3 (en) 2026-04-20
EP3773715A1 (fr) 2021-02-17
EP4327866A3 (fr) 2024-03-20

Similar Documents

Publication Publication Date Title
MA67901B1 (fr) Mirikizumab pour le traitement de la colite ulcéreuse
EA202091540A1 (ru) Антитела к lilrb2
SA519401522B1 (ar) Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
EA201792182A1 (ru) Композиции и способы для лечения анемии
MX2019001814A (es) Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart.
MA39906A (fr) Polythérapies pour le traitement du cancer
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
EA202092435A2 (ru) Моноклональные антитела против bcma
MA47604A (fr) Anticorps anti-pd-1 pour le traitement du cancer du poumon
MA52789A (fr) Méthodes de traitement du cancer avec des anticorps anti-pd-1
EP3494142A4 (fr) Anticorps anti-siglec-7 pour le traitement du cancer
CL2018000092A1 (es) Anticuerpos que se unen a la sortilina e inhiben la union de progranulina.
MX380557B (es) Anticuerpos específicos para cd38 para usarse en el tratamiento de mieloma múltiple (mm).
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
MA40592A (fr) Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7
EA202191666A1 (ru) Антитела к il-27 и их применение
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
MA45999A (fr) Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b
MA55558A (fr) Anticorps anti-cd73, anti-pd-l1 et chimiothérapie de traitement de tumeurs
EA201792124A1 (ru) Биотин для лечения амиотрофического латерального склероза
EA201692482A1 (ru) Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка